A High Content, High Throughput Cellular Thermal Stability Assay for Measuring Drug-target Engagement in Living Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Apr 5

PMID 29617433

Citations 12

Authors

Andrew J Massey

Affiliations

Soon will be listed here.

Abstract

Determining and understanding drug target engagement is critical for drug discovery. This can be challenging within living cells as selective readouts are often unavailable. Here we describe a novel method for measuring target engagement in living cells based on the principle of altered protein thermal stabilization / destabilization in response to ligand binding. This assay (HCIF-CETSA) utilizes high content, high throughput single cell immunofluorescent detection to determine target protein levels following heating of adherent cells in a 96 well plate format. We have used target engagement of Chk1 by potent small molecule inhibitors to validate the assay. Target engagement measured by this method was subsequently compared to target engagement measured by two alternative methods (autophosphorylation and CETSA). The HCIF-CETSA method appeared robust and a good correlation in target engagement measured by this method and CETSA for the selective Chk1 inhibitor V158411 was observed. However, these EC50 values were 23- and 12-fold greater than the autophosphorylation IC50. The described method is therefore a valuable advance in the CETSA method allowing the high throughput determination of target engagement in adherent cells.

Citing Articles

Thermal unfolding methods in drug discovery.

Llowarch P, Usselmann L, Ivanov D, Holdgate G Biophys Rev (Melville). 2024; 4(2):021305.

PMID: 38510342 PMC: 10903397. DOI: 10.1063/5.0144141.

Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson's disease.

Chen B, Zhang Q, Zhong X, Zhang X, Liu X, Wang H Cell Commun Signal. 2024; 22(1):75.

PMID: 38287374 PMC: 10823740. DOI: 10.1186/s12964-024-01478-0.

A Review of In Vitro Instrumentation Platforms for Evaluating Thermal Therapies in Experimental Cell Culture Models.

Chamani F, Barnett I, Pyle M, Shrestha T, Prakash P Crit Rev Biomed Eng. 2022; 50(2):39-67.

PMID: 36374822 DOI: 10.1615/CritRevBiomedEng.2022043455.

Monitoring drug-target interactions through target engagement-mediated amplification on arrays and in situ.

Al-Amin R, Johansson L, Abdurakhmanov E, Landegren N, Lof L, Arngarden L Nucleic Acids Res. 2022; 50(22):e129.

PMID: 36189884 PMC: 9825164. DOI: 10.1093/nar/gkac842.

Real-Time Cellular Thermal Shift Assay to Monitor Target Engagement.

Sanchez T, Ronzetti M, Owens A, Antony M, Voss T, Wallgren E ACS Chem Biol. 2022; 17(9):2471-2482.

PMID: 36049119 PMC: 9486815. DOI: 10.1021/acschembio.2c00334.

References

Massey A, Stokes S, Browne H, Foloppe N, Fiumana A, Scrace S . Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget. 2015; 6(34):35797-812. PMC: 4742142. DOI: 10.18632/oncotarget.5929. View

Massey A . Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage. Sci Rep. 2017; 7:40778. PMC: 5247758. DOI: 10.1038/srep40778. View

Han X, Tang J, Wang J, Ren F, Zheng J, Gragg M . Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage. J Biol Chem. 2016; 291(25):12951-9. PMC: 4933214. DOI: 10.1074/jbc.M115.713248. View

Huber K, Olek K, Muller A, Tan C, Bennett K, Colinge J . Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nat Methods. 2015; 12(11):1055-7. PMC: 4629415. DOI: 10.1038/nmeth.3590. View

Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P . The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014; 9(9):2100-22. DOI: 10.1038/nprot.2014.138. View

Wang J, Han X, Feng X, Wang Z, Zhang Y . Coupling cellular localization and function of checkpoint kinase 1 (Chk1) in checkpoints and cell viability. J Biol Chem. 2012; 287(30):25501-9. PMC: 3408180. DOI: 10.1074/jbc.M112.350397. View

Montano R, Chung I, Garner K, Parry D, Eastman A . Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2011; 11(2):427-38. PMC: 3277678. DOI: 10.1158/1535-7163.MCT-11-0406. View

McNulty D, Bonnette W, Qi H, Wang L, Ho T, Waszkiewicz A . A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1. SLAS Discov. 2017; 23(1):34-46. DOI: 10.1177/2472555217732014. View

Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson E, Dan C . Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013; 341(6141):84-7. DOI: 10.1126/science.1233606. View

10.

Chen P, Luo C, Deng Y, Ryan K, Register J, Margosiak S . The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell. 2000; 100(6):681-92. DOI: 10.1016/s0092-8674(00)80704-7. View

11.

Franken H, Mathieson T, Childs D, Sweetman G, Werner T, Togel I . Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015; 10(10):1567-93. DOI: 10.1038/nprot.2015.101. View

12.

Lackner D, Carre A, Guzzardo P, Banning C, Mangena R, Henley T . A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat Commun. 2015; 6:10237. PMC: 4703899. DOI: 10.1038/ncomms10237. View

13.

Savitski M, Reinhard F, Franken H, Werner T, Falth Savitski M, Eberhard D . Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014; 346(6205):1255784. DOI: 10.1126/science.1255784. View

14.

Geneste C, Massey A . Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discov. 2017; 23(2):144-153. DOI: 10.1177/2472555217738534. View

15.

Liu Q, Guntuku S, Cui X, Matsuoka S, Cortez D, Tamai K . Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000; 14(12):1448-59. PMC: 316686. View

16.

Massey A, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin N . mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Mol Oncol. 2015; 10(1):101-12. PMC: 5528927. DOI: 10.1016/j.molonc.2015.08.004. View

17.

Wayne J, Brooks T, Massey A . Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Oncotarget. 2016; 7(51):85033-85048. PMC: 5356717. DOI: 10.18632/oncotarget.13119. View

18.

Reinhard F, Eberhard D, Werner T, Franken H, Childs D, Doce C . Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat Methods. 2015; 12(12):1129-31. DOI: 10.1038/nmeth.3652. View

19.

He X, Tan C, Wang F, Wang Y, Zhou R, Cui D . Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 2016; 44(9):e85. PMC: 4872082. DOI: 10.1093/nar/gkw064. View

20.

Zhang Y, Hunter T . Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2013; 134(5):1013-23. PMC: 3852170. DOI: 10.1002/ijc.28226. View